New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
12:42 EDTNSR, PF, HSH, MRK, DG, PPC, GILD, ERIC, FDO, TSN, ACHN, IDIXOn The Fly: Midday Wrap
Stocks on Wall Street were higher at midday, pushing the S&P 500 and the Dow Jones Industrial Average toward new milestone levels. The market began the session just slightly below the flat-line, but within minutes had moved into positive territory where it has remained all morning. The averages have moved in a very narrow range, but the slow drift higher has the Dow within striking distance of 17,000 and the S&P edging closer to 2,000. ECONOMIC EVENTS: In the U.S., no significant economic data was reported. In Asia, data released over the weekend showed that China's trade surplus widened in May to $35.92B, as the nation's exports accelerated more than forecast and imports fell more than expected. COMPANY NEWS: Shares of several companies that have developed hepatitis C, or HCV, treatments were active after one such company, Idenix (IDIX), agreed to be acquired by pharmaceutical giant Merck (MRK) for $24.50 per share in cash. The purchase price is more than triple the company's closing price on Friday and Idenix shares rose more than 230% to trade near $24.09 after the announcement. Shares of Achillion Pharmaceuticals (ACHN), which has developed its own HCV drugs, were up 40% as investors speculate it could be the next takeover target in the space, while shares of Gilead (GILD) fell about 4% after an analyst wrote that Merck bought Idenix partly to strengthen its hand in patent litigation against Gilead... Food processor and distributor Hillshire Brands (HSH) advanced another 5% after Tyson Foods (TSN) increased its offer to acquire the company to $63 per share, prompting rival Pilgrim's Pride (PPC) to withdraw its own takeover proposal. However, Tyson's new offer is still subject to Hillshire being released from its existing agreement to acquire Pinnacle Foods (PF) and Hillshire said it does not have the right to break its merger pact with Pinnacle on the basis of the Tyson offer or enter into an agreement with Tyson prior to the termination. MAJOR MOVERS: Among the notable gainers was Family Dollar (FDO), which climbed 14% after well-known activist investor Carl Icahn disclosed that he had obtained a significant stake in the company. Also higher were shares of peer Dollar General (DG), which gained nearly 10% after Icahn reportedly told Fox Business that he may push for a merger between the two dollar store operators. Among the noteworthy losers was Neustar (NSR), which dropped 7.5% after acknowledging a copy of a confidential email was posted in the FCC docket and made available to the public. Deutsche Bank noted that shares of NeuStar traded down just before the close on Friday after the posting, which suggested the North American Numbering Council has recommended selecting iConectiv, the Telcordia unit of Ericsson (ERIC), as the vendor for the Number Portability Administration Center in place of incumbent Neustar. INDEXES: Near midday, the Dow was up 31.57, or 0.19%, to 16,955.85, the Nasdaq was up 22.30, or 0.52%, to 4,343.70, and the S&P 500 was up 3.92, or 0.2%, to 1,953.36.
News For IDIX;MRK;ACHN;GILD;HSH;TSN;PPC;PF;FDO;DG;NSR;ERIC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 27, 2015
08:32 EDTMRKMerck receives 'positive' CHMP opinion for Zerbaxa
Subscribe for More Information
07:37 EDTMRKAeterna Zentaris starts promoting Saizen for injection in 25 U.S. territories
Subscribe for More Information
05:56 EDTGILDStocks with implied volatility movement; CRM GILD
Subscribe for More Information
05:36 EDTERICEricsson announces partnership with Airtel Gabon
Subscribe for More Information
July 24, 2015
06:27 EDTGILDGilead price target raised to $131 from $120 at Piper Jaffray
Subscribe for More Information
July 23, 2015
12:45 EDTGILDGilead July weekly volatility elevated into Q2 and outlook
Subscribe for More Information
11:04 EDTMRKMerck announces EMA acceptance of MAA for grazoprevir/elbasvir
Subscribe for More Information
July 22, 2015
07:04 EDTMRKMerck's Keytruda approved by EU for treatment of advanced melanoma in adults
Merck announced that the European Commission has approved KEYTRUDA, the company’s anti-PD-1 therapy, for the treatment of advanced melanoma in adults. The European Commission approval of pembrolizumab is based on data from three clinical studies conducted in more than 1,500 first-line and previously-treated patients with advanced melanoma. Pembrolizumab received European Commission regulatory approval based on Phase 3 data which showed it is the first and only anti-PD-1 therapy to provide a statistically superior survival benefit as a monotherapy compared to ipilimumab, the current standard of care for advanced melanoma. Today’s approval allows marketing of pembrolizumab in all 28 EU member states at the approved dose of 2 mg/kg every three weeks. The European Commission’s approval is based on data from three studies -- KEYNOTE-001, KEYNOTE-002 and KEYNOTE-006. These studies evaluated the efficacy and safety of pembrolizumab in advanced melanoma patients – across treatment lines, prognostic factors, tumor characteristics, and BRAF mutational status – and established 2 mg/kg every three weeks as the approved dose.
06:05 EDTMRKMerck, Ablynx expand immuno-oncology collaboration
Subscribe for More Information
July 21, 2015
14:12 EDTGILDGilead reports study of E/C/F/TAF met primary endpoint
Gilead Sciences announced detailed 48-week data from an open-label Phase 3 study evaluating its investigational once-daily single tablet regimen of elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg, or E/C/F/TAF, among 1,436 virologically suppressed adult patients switching from tenofovir disoproxil fumarate-containing regimens. The study met its primary endpoint by demonstrating non-inferiority of E/C/F/TAF to the TDF-based regimens at Week 48. The study also demonstrated statistical superiority among patients with HIV-1 RNA levels less than 50 copies/mL at Week 48 and statistically significant improvements in bone and renal laboratory parameters. These data were presented in an oral session at the 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention in Vancouver, Canada. Among the 1,436 patients who were randomized in the study, virologic success rates at Week 48 were higher in patients taking E/C/F/TAF, 97% versus 93% for all TDF-based regimens; difference in percentages: 4.1%, 95% CI: 1.6% to 6.7%. The rates of virologic failure were similar between the two arms, with E/C/F/TAF, 1.0% and TDF-based regimen, 1.3%. General safety was similar between the two arms through 48 weeks of treatment, with similar percentages of patients in each group having any adverse events. Adverse events leading to treatment discontinuation were more common among patients treated with a TDF-based regimen.
July 20, 2015
07:33 EDTGILDInternational AIDS Society to hold a conference
Subscribe for More Information
July 17, 2015
13:29 EDTERICWireless infrastructure shares up after Ericsson,TESSCO report
Subscribe for More Information
10:21 EDTGILDCigna says 98.4% of customers treated with hep C drug Harvoni are cured
Subscribe for More Information
09:03 EDTGILDGilead granted orphan status for gastric cancer treatment
Subscribe for More Information
05:36 EDTERICEricsson says global cost and efficiency program progressing according to plan
Ericsson announced that the target to achieve savings of approximately SK 9B during 2017 relative to 2014, remains. During the quarter, numerous activities were implemented globally including a reduction of 2,100 positions in Sweden, resulting in higher than normal restructuring charges. Savings related to the activities will start to impact results towards the end of this year.
05:34 EDTERICEricsson reports Q2 non-IFRS EPS SK 1.45 vs. SK 1.07 last year
Subscribe for More Information
July 16, 2015
10:00 EDTPFOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:22 EDTGILDBristol-Myers says EU approves Evotaz for treatment of HIV-1 infection in adults
Subscribe for More Information
06:36 EDTPFPinnacle Foods downgraded to Hold from Buy at Deutsche Bank
Subscribe for More Information
05:34 EDTERICEricsson announces collaboration with Softbank on 5G trials in Tokyo
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use